Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People who have been diagnosed with small cell lung cancer (SCLC) that has spread widely in the body (called extensive-stage SCLC), confirmed through a tissue or cell sample test.
- For the Phase I part of the trial: People whose cancer has continued to grow or spread after receiving at least one chemotherapy treatment (which included a platinum-based chemotherapy combined with a type of immunotherapy called a PD-L1 inhibitor), unless a doctor determined those treatments were not suitable for them.
- For the Phase II part of the trial: People who have already received a platinum-based chemotherapy combined with a PD-L1 inhibitor immunotherapy, unless a doctor determined those treatments were not suitable for them. Previous treatment with a DLL3-targeted therapy is not allowed in Phase II (it is allowed in Phase I).
- People who have at least one area of cancer that can be measured on a scan, as defined by standard medical guidelines.
- People who are generally well enough to carry out light daily activities (a level rated 0 or 1 on a standard health scale used in cancer research).
- People who have a tumour tissue sample available from within the past 6 months, or who are willing to have a new tissue biopsy taken at the start of the trial if no recent sample exists (exceptions may be considered if a new biopsy is not medically possible, after discussion with the study medical team).
- People who a doctor determines are well enough to go through a preparatory treatment process called lymphodepletion.
- People whose cell collection process (called apheresis) produces a sample that is accepted for use in manufacturing the trial treatment.
Who may not be able to join:
- People who have previously received any genetically modified cell therapy, including any CAR-T cell therapy that targeted DLL3.
- People with brain or spinal fluid involvement from their cancer that is unstable or causing symptoms (people with stable brain spread may still be considered if they meet specific study requirements — confirm with trial site).
- People with seizures that are not well controlled.
- People with serious active infections, including active Hepatitis B, Hepatitis C, or HIV.
- People who have another cancer that is currently growing or requires ongoing treatment, with some exceptions as outlined in the study details (confirm with trial site).
- People who have previously had an organ transplant or a bone marrow/stem cell transplant from another person.
- People with significant existing problems affecting the lungs, heart, liver, kidneys, or nervous system, as defined by specific measurements in the study guidelines (confirm with trial site).
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All study parts: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); All study parts: Incidence and severity of dose-limiting toxicities (DLTs); Phase II Group A: Overall response rate (ORR) as per RECIST v1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.